US 12344665
Treatment of fibrodysplasia ossificans progressiva by administration of an anti-activin a antibody
granted A61KA61K2039/505A61K39/395
Quick answer
US patent 12344665 (Treatment of fibrodysplasia ossificans progressiva by administration of an anti-activin a antibody) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 17
- CPC classes
- A61K, A61K2039/505, A61K39/395, A61K39/3955, A61P